High cost of new pancreatic cancer drug limits patient access in Manitoba
Daraxonrasib (Rasonque), a pancreatic cancer pill approved by the U.S. FDA in August but not yet in Canada, costs about $90,000 Cdn a month - Vancouver patient James Howard pays about $63,000 US a month for three daily doses. Its launch price is $480,000 US ($675,000 Cdn) a year. Trials showed it halted or reversed tumour growth in nearly a third of patients, versus about 10% on chemotherapy, and lifted survival from under 7 months to about 13. Oncologists say the price puts a life-extending drug out of reach; the maker says it reflects therapeutic advance and supports innovation.
CancerCare Manitoba oncologist Dr. Ralph Wong says patients in his practice are crying because they cannot access this drug, which is not yet approved in Canada - a stark example of how U.S. drug pricing leaves Canadians paying out of pocket or going without.
Ask about this brief
Answers are written by AI from this brief and can be wrong. Check the original source before you act.
2 free questions a day without an account. Members ask as often as they like, free.
Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.
Read the original
News source: High cost of new pancreatic cancer drug limits patient access in Manitoba (opens in a new tab) — CBC News
